Evidence map›Paper›PMID 25736375›Full record

ArticleThe EMBO journal2015

SIGNing a symbiotic treaty with gut microbiota.

Geanncarlo Lugo-Villarino, Olivier Neyrolles

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The EMBO journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Geanncarlo Lugo-VillarinoDépartement Tuberculosis and Infection Biology, Institut de Pharmacologie et de Biologie Structurale (IPBS) CNRS, Toulouse, France UPS, IPBS Université Paul Sabatier Université de Toulouse, Toulouse, France.
Olivier NeyrollesDépartement Tuberculosis and Infection Biology, Institut de Pharmacologie et de Biologie Structurale (IPBS) CNRS, Toulouse, France UPS, IPBS Université Paul Sabatier Université de Toulouse, Toulouse, France.
Université Fédérale de Toulouse Midi-Pyrénées · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Beneficial microbes hold great promise for the treatment of a wide range of immune and inflammatory disorders. In this issue of The EMBO Journal, Lightfoot and colleagues report how the food-grade bacterium Lactobacillus acidophilus helps the immune system to limit experimental colitis in mice through interaction between SIGNR3 and surface layer protein A (SlpA) in L. acidophilus. These results pave the way for future development of novel therapies for inflammatory diseases, including inflammatory bowel disease.

Indexed as

AnimalsAntigens, CDBacterial ProteinsInflammatory Bowel DiseasesIntestinal MucosaLactobacillus acidophilusLectins, C-TypeAntigens, CDBacterial ProteinsLectins, C-TypeSIGNR3 protein, mousesurface layer protein A, Bacteria

Identifiers

PMID25736375
PMCPMC4388591
OpenAlexW2141876822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.